Opinion|Videos|April 9, 2025
Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies
Author(s)Caron A. Jacobson, MD, MMSc, Peter Riedell, MD
Experts discuss when to consider chimeric antigen receptor T-cell therapy (CAR T) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients and how to sequence CAR T and pirtobrutinib in clinical practice for those who have previously received both covalent Bruton tyrosine kinase (cBTK) inhibitor– and BCL2 inhibitor–containing regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Shifting focus to CLL, Dr Riedell,at what point do you consider CAR T-cell therapy for your R/R CLL patients?
- How do you sequence between CAR T and pirtobrutinib in your clinical practice for those who have previously received both cBTK inhibitor– and BCL2 inhibitor–containing regimens?
Advertisement
Related to this article
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
5